Taysha Gene Therapies
TSHA
3.72
-0.05
-1.33%
Taysha Gene Therapies
US · TSHA
#3015 by market cap
Listed 2020
3.72
-0.05
-1.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/5/7
-
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14Market Newswire · 2026/11/14
-
Rating change
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14Market Newswire · 2026/6/23
-
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/11/13
-
Rating change
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/8/12
-
Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/10/16
-
Rating change
Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $12Market Newswire · 2026/6/30
-
Rating change
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15Market Newswire · 2026/7/1
-
Rating change
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/6/23
-
Rating change
Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)TipRanks · 2026/6/30
-
Rating change
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19Market Newswire · 2026/8/12
-
Rating change
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2026/6/1
-
Rating change
Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy RatingMarket Newswire · 2026/9/17
-
Rating change
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/5/22
-
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q3 Net Loss $0.10 a Share, Vs. FactSet Est of $0.13 LossMT Newswires · 2026/11/12
-
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy RatingMarket Newswire · 2026/8/14
-
Rating change
Citizens JMP Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $11Market Newswire · 2026/6/23
-
Rating change
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13Market Newswire · 2026/8/12
-
Rating change
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15Market Newswire · 2026/6/30
-
Rating change
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13Market Newswire · 2026/7/22
-
Rating change
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/8/12
-
Rating change
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17Market Newswire · 2026/4/6
-
Rating change
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14Market Newswire · 2026/7/1
-
Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/8/12
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.
Taysha Gene Therapies discussion 0 comments